百诚医药：创新药 BIOS-0625 片获得临床试验批准
Bio-SBio-S(SZ:301096) Xin Lang Cai Jing·2025-11-07 12:33

Core Viewpoint - The company has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug BIOS-0625, aimed at treating ulcerative colitis [1] Group 1 - The drug BIOS-0625 is classified as a Class 1 medication [1] - The clinical trial application for BIOS-0625 was accepted by NMPA on August 28, 2025 [1] - The clinical trials will focus on the treatment of ulcerative colitis [1]